Results 81 to 90 of about 11,898 (160)

Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis. [PDF]

J Neurol
Muñoz-Vendrell A, Arroyo-Pereiro P, León I, Bau L, Matas E, Romero-Pinel L, Roca-Pereira S, Martínez-Yélamos A, Martínez-Yélamos S.   +8 more
europepmc   +1 more source

Visual and Neuro-Ophthalmic Manifestations of John Cunningham (JC) Virus-Related Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Systematic Review. [PDF]

Cureus
Jangirashvili T, Parthiv O, Shengelia L, Tabeshadze Z, Kontchoshvili A, Waked CA, Tamer RM.   +6 more
europepmc   +1 more source

Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis. [PDF]

Front Immunol
Buhelt S, Hansen MB, Søndergaard HB, El Mahdaoui S, Hansen MM, Mahler MR, Romme Christensen J, Sellebjerg F.   +7 more
europepmc   +1 more source

Do apelin and ghrelin play a role in multiple sclerosis? The analysis of patients treated with immunomodulatory therapies. [PDF]

Front Immunol
Adamczyk B, Morawiec N, Rakoca M, Sowa A, Sawa K, Adamczyk-Sowa M.   +5 more
europepmc   +1 more source

The wearing-off effect with natalizumab: Back to the drawing board. [PDF]

Neurotherapeutics
Afzal S, Conway DS.
europepmc   +1 more source

Trajectories of processing speed in multiple sclerosis across disease-modifying therapies. [PDF]

J Neurol
Guo J, Johansson E, Hillert J, Olsson T, Alfredsson L, Hedström AK.   +5 more
europepmc   +1 more source

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges. [PDF]

Neurol Ther
Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J.   +11 more
europepmc   +1 more source

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy

ClinicoEconomics and Outcomes Research
Luca Prosperini,1 Lorenzo Pradelli,2 Laura Santoni,3 Daria Perini,3 Salvatore Cottone,4 Marco Vercellino5 1S. Camillo-Forlanini Hospital, Rome, Italy; 2AdRes Health Economics and Outcomes Resources, Turin, Italy; 3Biogen Italia, Milan, Italy; 4Department
Prosperini L, Pradelli L, Santoni L, Perini D, Cottone S, Vercellino M   +5 more
doaj  

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source

Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis. [PDF]

Neurol Ther
Chisari CG, Crimì P, Spampinato G, Ferraro E, Alecci A, Lo Fermo S, Cimino V, Zappia M, Patti F.   +8 more
europepmc   +1 more source